Trials / Completed
CompletedNCT01431937
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682. The study will also provide further evidence of the potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on Absolute Lymphocyte Counts (ALC).
Detailed description
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682. The study will also provide further evidence of the potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on Absolute Lymphocyte Counts (ALC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK2018682 | Active Drug |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2010-10-10
- Primary completion
- 2011-03-29
- Completion
- 2011-03-29
- First posted
- 2011-09-12
- Last updated
- 2017-07-07
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT01431937. Inclusion in this directory is not an endorsement.